Figure 1.
Figure 1. Comparison of standard-dose to high-dose daunorubicin (E1900). (A) All patients—OS. (B) Favorable and intermediate-risk cytogenetic patients—OS.

Comparison of standard-dose to high-dose daunorubicin (E1900). (A) All patients—OS. (B) Favorable and intermediate-risk cytogenetic patients—OS.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal